Alerte De Sécurité sur Commercial name: Bone Densitometry / Densitometer Osseo Lunar Dpx / Osseo Lunar Densitometer Dpx / Bone Densitometer Prodigy. Technical Name: Bone Desensiometry Apparatus. ANVISA registration number: 80071260174; 80071260176; 80035360019; 80071260163 ;. Risk class: III. Affected Model: DPX Bravo, DPX-Duo (80071260174) / DPX-NT (80071260176) / DPX-MD + (80035360019) / Prodigy, Prodigy Advance (80071260163). Lots of numbers affected: PA + 130268; LNR41569; LNR74315; LNR150180; LNR73479

Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.

You can continue using your system by turning off the DICOM MPPS feature as follows: 1. In enCORE, select Tools | Connectivity Options. 2. Select the DICOM tab. 3. Press Configure Connections in the DICOM Worklist section. 4. In the MPPS SCP settings, clear the Title AE and TCP / IP Address fields. 5. Press OK for all. According to the company, a GE Healthcare representative will contact users to schedule the fix. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 07/09/2017 - Date of notification notice to Anvisa: 04/24/2018 The company that owns the affected product is responsible for contacting its customers in due time. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "